Showing 1711-1720 of 5771 results for "".
- Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-announces-new-commercial-and-medicare-coverage-for-eysuvis/2480834/Kala Pharmaceuticals announced that the largest Pharmacy Benefit Manager in the United States has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 1, 2022. This adds 28.5 million people to Eysuvis coverage,
- Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-detailed-18-month-results-from-phase-3-derby-and-oaks-studies-of-pegcetacoplan-for-geographic-atrophy-ga-at-arvo/2480830/Apellis Pharmaceuticals announced detailed, longer-term data from the phase 3 DERBY and OAKS studies of intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Monthly and
- Tarsus Announces Positive Topline Data from Saturn-2 Phase 3 Trial of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-announces-positive-topline-data-from-saturn-2-phase-3-the-second-pivotal-trial-of-tp-03-for-the-treatment-of-demodex-blepharitis/2480827/Tarsus Pharmaceuticals announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal phase 3 trial with a favorable safety profile, reinforcing its ability to resolve Demodex blepharitis. With these
- Atsena Therapeutics Announces Presentations at ARVO and ASGCThttps://modernod.com/news/atsena-therapeutics-announces-presentations-at-arvo-and-asgct/2480825/Atsena Therapeutics announced that research on two of its next-generation adeno-associated virus (AAV) technologies will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, and the American Society of Gene & Cell Therapy (ASGC
- Opthea Presenting Clinical Data at ARVO 2022 Annual Meetinghttps://modernod.com/news/opthea-presenting-clinical-data-at-arvo-2022-annual-meeting/2480820/Opthea announced the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 conference, taking place in Denver, Colorado from May 1-4, 2022 and virtually from May 11-12, 2022. Jason Slakter, MD, of
- Bausch + Lomb Announces Launch of IPOhttps://modernod.com/news/bausch-lomb-announces-launch-of-ipo/2480816/Bausch + Lomb announced the launch of its initial public offering (IPO) and the commencement of the roadshow for the IPO. Bausch + Lomb, which is being spun out of Bausch Health, plan to sell 35 million common shares for $21 to $24 per share, for a valuation of as much $8.4 billion
- Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meetinghttps://modernod.com/news/graybug-to-present-preclinical-data-for-gb-401-in-primary-open-angle-glaucoma-at-the-2022-arvo-annual-meeting/2480808/Graybug Vision announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 20
- Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meetinghttps://modernod.com/news/allegro-ophthalmics-announces-new-scientific-data-to-be-presented-during-the-2022-arvo-annual-meeting/2480806/Allegro Ophthalmics announced that two scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. ARVO 2022 will be held May 1-4, 2022 in
- Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meetinghttps://modernod.com/news/visus-therapeutics-announces-new-scientific-data-to-be-presented-during-the-2022-arvo-annual-meeting/2480805/Visus Therapeutics announced that it will present new scientific data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 1-4, 2022 in Denver, Colorado. The two presentations will highlight topics on new research findings on Brimochol PF, th
- Apellis Announces Results from New Survey Revealing the Emotional Burden Caused by Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-results-from-new-survey-revealing-the-emotional-burden-caused-by-geographic-atrophy-ga/2480801/Apellis Pharmaceuticals announced results from a global survey conducted by The Harris Poll, which found that living with geographic atrophy (GA) can cause a substantial emotional burden and impact on independence. GA is a leading cause of blindness that affects more than 5 million people wo